Cullinan Therapeutics: Heading Toward Paydirt
Cullinan Therapeutics Inc CGEM
$15.05
▲ +4.22%
(+$0.61)
Open
$14.81
Prev Close
$14.44
Day Range
$14.34 – $15.57
52W Range
$5.68 – $16.74
Market Cap
$923.71M
Beta
0.07
EPS (TTM)
$-3.72
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-01-08 |
| Shares Out. | 61,460,000 |
| Website | cullinantherapeutics.com/ ↗ |
| Phone | 16174104650 |
Cullinan Therapeutics Inc is a publicly traded company under the ticker symbol CGEM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-06-01)
📰 Latest News for CGEM
Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases - Slideshow
Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-978, CD19xCD3 T Cell Engager, And Velinotamig, BCMAxCD3 T Cell Engager
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE And RA Patients Following Single Target Dose In Phase 1 Trial